Human Gene GNAI3 (ENST00000369851.7_5) from GENCODE V47lift37
  Description: G protein subunit alpha i3 (from RefSeq NM_006496.4)
Gencode Transcript: ENST00000369851.7_5
Gencode Gene: ENSG00000065135.12_9
Transcript (Including UTRs)
   Position: hg19 chr1:110,091,237-110,142,817 Size: 51,581 Total Exon Count: 9 Strand: +
Coding Region
   Position: hg19 chr1:110,091,343-110,134,855 Size: 43,513 Coding Exon Count: 8 

Page IndexSequence and LinksUniProtKB CommentsPrimersMalaCardsCTD
Gene AllelesRNA-Seq ExpressionMicroarray ExpressionRNA StructureProtein StructureOther Species
GO AnnotationsmRNA DescriptionsPathwaysOther NamesModel InformationMethods
Data last updated at UCSC: 2024-08-22 23:36:26

-  Sequence and Links to Tools and Databases
 
Genomic Sequence (chr1:110,091,237-110,142,817)mRNA (may differ from genome)Protein (354 aa)
Gene SorterGenome BrowserOther Species FASTAVisiGeneGene interactionsTable Schema
AlphaFoldBioGPSEnsemblEntrez GeneExonPrimerGeneCards
HGNCMalacardsMGIOMIMPubMedReactome
UniProtKBWikipediaBioGrid CRISPR DB

-  Comments and Description Text from UniProtKB
  ID: GNAI3_HUMAN
DESCRIPTION: RecName: Full=Guanine nucleotide-binding protein G(k) subunit alpha; AltName: Full=G(i) alpha-3;
FUNCTION: Guanine nucleotide-binding proteins (G proteins) are involved as modulators or transducers in various transmembrane signaling systems. G(k) is the stimulatory G protein of receptor- regulated K(+) channels. The active GTP-bound form prevents the association of RGS14 with centrosomes and is required for the translocation of RGS14 from the cytoplasm to the plasma membrane. May play a role in cell division.
SUBUNIT: G proteins are composed of 3 units; alpha, beta and gamma. The alpha chain contains the guanine nucleotide binding site. Interacts with GPSM1. Interacts (via active GTP- or inactive GDP-bound form) with RGS14 (By similarity).
SUBCELLULAR LOCATION: Cytoplasm. Cell membrane. Cytoplasm, cytoskeleton, centrosome. Note=Localizes in the centrosomes of interphase and mitotic cells. Detected at the cleavage furrow and/or the midbody.
DISEASE: Defects in GNAI3 are the cause of auriculocondylar syndrome 1 (ARCND1) [MIM:602483]. ARCND1 is an autosomal dominant craniofacial malformation syndrome characterized by variable mandibular anomalies, including mild to severe micrognathia, temporomandibular joint ankylosis, cleft palate, and a characteristic ear malformation that consists of separation of the lobule from the external ear, giving the appearance of a question mark (question-mark ear). Other frequently described features include prominent cheeks, cupped and posteriorly rotated ears, preauricular tags, and microstomia.
SIMILARITY: Belongs to the G-alpha family. G(i/o/t/z) subfamily.

-  Primer design for this transcript
 

Primer3Plus can design qPCR Primers that straddle exon-exon-junctions, which amplify only cDNA, not genomic DNA.
Click here to load the transcript sequence and exon structure into Primer3Plus

Exonprimer can design one pair of Sanger sequencing primers around every exon, located in non-genic sequence.
Click here to open Exonprimer with this transcript

To design primers for a non-coding sequence, zoom to a region of interest and select from the drop-down menu: View > In External Tools > Primer3


-  MalaCards Disease Associations
  MalaCards Gene Search: GNAI3
Diseases sorted by gene-association score: auriculocondylar syndrome 1* (1228), auriculo-condylar syndrome* (175), ankylosis (7)
* = Manually curated disease association

-  Comparative Toxicogenomics Database (CTD)
  The following chemicals interact with this gene           more ... click here to view the complete list

+  Common Gene Haplotype Alleles
  Press "+" in the title bar above to open this section.

-  RNA-Seq Expression Data from GTEx (53 Tissues, 570 Donors)
  Highest median expression: 38.66 RPKM in Esophagus - Mucosa
Total median expression: 919.09 RPKM



View in GTEx track of Genome Browser    View at GTEx portal     View GTEx Body Map

+  Microarray Expression Data
  Press "+" in the title bar above to open this section.

-  mRNA Secondary Structure of 3' and 5' UTRs
 
RegionFold EnergyBasesEnergy/Base
Display As
5' UTR -35.40106-0.334 Picture PostScript Text
3' UTR -2283.407873-0.290 Picture PostScript Text

The RNAfold program from the Vienna RNA Package is used to perform the secondary structure predictions and folding calculations. The estimated folding energy is in kcal/mol. The more negative the energy, the more secondary structure the RNA is likely to have.

-  Protein Domain and Structure Information
  InterPro Domains: Graphical view of domain structure
IPR001408 - Gprotein_alpha_I
IPR001019 - Gprotein_alpha_su
IPR011025 - GproteinA_insert

Pfam Domains:
PF00025 - ADP-ribosylation factor family
PF00503 - G-protein alpha subunit

SCOP Domains:
47895 - Transducin (alpha subunit), insertion domain
52540 - P-loop containing nucleoside triphosphate hydrolases

Protein Data Bank (PDB) 3-D Structure
MuPIT help
2IHB - X-ray MuPIT 2ODE - X-ray MuPIT 2V4Z - X-ray MuPIT 4G5O - X-ray MuPIT 4G5R - X-ray MuPIT 4G5S - X-ray MuPIT


ModBase Predicted Comparative 3D Structure on P08754
FrontTopSide
The pictures above may be empty if there is no ModBase structure for the protein. The ModBase structure frequently covers just a fragment of the protein. You may be asked to log onto ModBase the first time you click on the pictures. It is simplest after logging in to just click on the picture again to get to the specific info on that model.

-  Orthologous Genes in Other Species
  Orthologies between human, mouse, and rat are computed by taking the best BLASTP hit, and filtering out non-syntenic hits. For more distant species reciprocal-best BLASTP hits are used. Note that the absence of an ortholog in the table below may reflect incomplete annotations in the other species rather than a true absence of the orthologous gene.
MouseRatZebrafishD. melanogasterC. elegansS. cerevisiae
No orthologNo orthologNo orthologNo orthologNo orthologNo ortholog
Gene DetailsGene Details    
Gene SorterGene Sorter    
 RGD    
      
      

-  Gene Ontology (GO) Annotations with Structured Vocabulary
  Molecular Function:
GO:0000166 nucleotide binding
GO:0001664 G-protein coupled receptor binding
GO:0003924 GTPase activity
GO:0004871 signal transducer activity
GO:0005515 protein binding
GO:0005525 GTP binding
GO:0019001 guanyl nucleotide binding
GO:0019003 GDP binding
GO:0019904 protein domain specific binding
GO:0031683 G-protein beta/gamma-subunit complex binding
GO:0031821 G-protein coupled serotonin receptor binding
GO:0032794 GTPase activating protein binding
GO:0046872 metal ion binding

Biological Process:
GO:0006457 protein folding
GO:0006906 vesicle fusion
GO:0007049 cell cycle
GO:0007165 signal transduction
GO:0007186 G-protein coupled receptor signaling pathway
GO:0007188 adenylate cyclase-modulating G-protein coupled receptor signaling pathway
GO:0007193 adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway
GO:0007194 negative regulation of adenylate cyclase activity
GO:0007212 dopamine receptor signaling pathway
GO:0007420 brain development
GO:0016239 positive regulation of macroautophagy
GO:0032930 positive regulation of superoxide anion generation
GO:0033864 positive regulation of NAD(P)H oxidase activity
GO:0046039 GTP metabolic process
GO:0051301 cell division
GO:1904707 positive regulation of vascular smooth muscle cell proliferation
GO:2001234 negative regulation of apoptotic signaling pathway

Cellular Component:
GO:0005634 nucleus
GO:0005730 nucleolus
GO:0005737 cytoplasm
GO:0005765 lysosomal membrane
GO:0005794 Golgi apparatus
GO:0005813 centrosome
GO:0005815 microtubule organizing center
GO:0005834 heterotrimeric G-protein complex
GO:0005856 cytoskeleton
GO:0005886 plasma membrane
GO:0016020 membrane
GO:0030496 midbody
GO:0042588 zymogen granule
GO:0045121 membrane raft
GO:0070062 extracellular exosome
GO:0000139 Golgi membrane
GO:0005789 endoplasmic reticulum membrane


-  Descriptions from all associated GenBank mRNAs
  BC025285 - Homo sapiens guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 3, mRNA (cDNA clone MGC:39207 IMAGE:5433334), complete cds.
J03238 - Human GTP-binding protein mRNA, complete cds.
AK312252 - Homo sapiens cDNA, FLJ92547, Homo sapiens guanine nucleotide binding protein (G protein), alphainhibiting activity polypeptide 3 (GNAI3), mRNA.
AK311691 - Homo sapiens cDNA, FLJ18733.
J03198 - Human stimulatory G protein (of receptor-regulated K+ channels) alpha subunit mRNA, complete cds.
M27543 - Human guanine nucleotide-binding protein (Gi) alpha subunit mRNA, complete cds.
AB463705 - Synthetic construct DNA, clone: pF1KB6468, Homo sapiens GNAI3 gene for guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 3, without stop codon, in Flexi system.
DQ892862 - Synthetic construct clone IMAGE:100005492; FLH190401.01X; RZPDo839H1075D guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 3 (GNAI3) gene, encodes complete protein.
DQ896111 - Synthetic construct Homo sapiens clone IMAGE:100010571; FLH190397.01L; RZPDo839H1065D guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 3 (GNAI3) gene, encodes complete protein.
CU692958 - Synthetic construct Homo sapiens gateway clone IMAGE:100021921 5' read GNAI3 mRNA.
KJ891257 - Synthetic construct Homo sapiens clone ccsbBroadEn_00651 GNAI3 gene, encodes complete protein.
BT019973 - Homo sapiens guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 3 mRNA, complete cds.
BT019974 - Homo sapiens guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 3 mRNA, complete cds.
AF493907 - Homo sapiens guanine nucleotide binding protein alpha i3 (GNAI3) mRNA, complete cds.
J03005 - Human alternative guanine nucleotide-binding regulatory protein (G) alpha-inhibitory-subunit mRNA, complete cds.
AK130069 - Homo sapiens cDNA FLJ26559 fis, clone LNF02778.
JD044195 - Sequence 25219 from Patent EP1572962.
JD553615 - Sequence 534639 from Patent EP1572962.
JD239070 - Sequence 220094 from Patent EP1572962.
JD355456 - Sequence 336480 from Patent EP1572962.
JD351974 - Sequence 332998 from Patent EP1572962.
JD545621 - Sequence 526645 from Patent EP1572962.
JD559826 - Sequence 540850 from Patent EP1572962.
JD155579 - Sequence 136603 from Patent EP1572962.
JD303998 - Sequence 285022 from Patent EP1572962.
JD108594 - Sequence 89618 from Patent EP1572962.
JD305847 - Sequence 286871 from Patent EP1572962.
JD559742 - Sequence 540766 from Patent EP1572962.
JD193506 - Sequence 174530 from Patent EP1572962.
JD040461 - Sequence 21485 from Patent EP1572962.
JD347409 - Sequence 328433 from Patent EP1572962.
JD299453 - Sequence 280477 from Patent EP1572962.
JD551924 - Sequence 532948 from Patent EP1572962.
JD110707 - Sequence 91731 from Patent EP1572962.
JD088828 - Sequence 69852 from Patent EP1572962.
JD436071 - Sequence 417095 from Patent EP1572962.
JD087578 - Sequence 68602 from Patent EP1572962.
JD440842 - Sequence 421866 from Patent EP1572962.
JD245990 - Sequence 227014 from Patent EP1572962.
JD110396 - Sequence 91420 from Patent EP1572962.
JD454254 - Sequence 435278 from Patent EP1572962.
JD166492 - Sequence 147516 from Patent EP1572962.
JD561873 - Sequence 542897 from Patent EP1572962.
JD448075 - Sequence 429099 from Patent EP1572962.
JD255386 - Sequence 236410 from Patent EP1572962.
JD564486 - Sequence 545510 from Patent EP1572962.
JD564488 - Sequence 545512 from Patent EP1572962.
JD564487 - Sequence 545511 from Patent EP1572962.
JD558377 - Sequence 539401 from Patent EP1572962.
JD558376 - Sequence 539400 from Patent EP1572962.
CS266452 - Sequence 144 from Patent WO2005118806.
DI443634 - KR 1020140074997-A/255: MICRORNAS IN NEURODEGENERATIVE DISORDERS.
DL076614 - METHODS AND COMPOSITIONS INVOLVING MicroRNA.
DM004264 - METHODS AND COMPOSITIONS INVOLVING MIRNA AND MIRNA INHIBITOR MOLECULES.
DM175406 - A nucleics Acid regulating cell growth.
FU261270 - MICRORNA EXPRESSION ABNORMALITIES IN PANCREATIC ENDOCRINE AND ACINAR TUMORS.
FU763772 - MICRORNA FINGERPRINTS DURING HUMAN MEGAKARYOCYTOPOIESIS.
FV525880 - Nucleic acid controling mast cell degranulation.
FW421606 - METHODS AND COMPOSITIONS INVOLVING MIRNA AND MIRNA INHIBITOR MOLECULES.
HV304671 - JP 2009531018-A/238: MICRORNA-BASED METHODS AND COMPOSITIONS FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF LUNG CANCER.
HV305169 - JP 2009531019-A/238: MICRORNA-BASED METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF SOLID CANCERS.
HW119378 - JP 2013046612-A/238: MICRORNA-BASED METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF SOLID CANCERS.
HW367477 - JP 2012228254-A/144: METHODS AND COMPOSITIONS INVOLVING MIRNA AND MIRNA INHIBITOR MOLECULES.
HW411870 - JP 2014000079-A/144: METHODS AND COMPOSITIONS INVOLVING MicroRNA.
HW581816 - JP 2014511677-A/8: DISTINGUISHING BENIGN AND MALIGNANT INDETERMINATE THYROID LESIONS.
HW589707 - JP 2013121348-A/238: MICRORNA FINGERPRINTS DURING HUMAN MEGAKARYOCYTOPOIESIS.
HW674216 - JP 2014217381-A/144: METHODS AND COMPOSITIONS INVOLVING MIRNA AND MIRNA INHIBITOR MOLECULES.
HW807960 - JP 2014534810-A/255: MICRORNAS IN NEURODEGENERATIVE DISORDERS.
HZ067158 - JP 2014012020-A/144: METHODS AND COMPOSITIONS INVOLVING MIRNA AND MIRNA INHIBITOR MOLECULES.
HZ408331 - JP 2015528002-A/928: CHIRAL CONTROL.
HZ413511 - JP 2014060993-A/238: MICRORNA-BASED METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF SOLID CANCERS.
HZ427582 - JP 2014217384-A/144: METHODS AND COMPOSITIONS INVOLVING MIRNA AND MIRNA INHIBITOR MOLECULES.
HZ428385 - JP 2014217385-A/144: METHODS AND COMPOSITIONS INVOLVING MIRNA AND MIRNA INHIBITOR MOLECULES.
HZ429188 - JP 2014217386-A/144: METHODS AND COMPOSITIONS INVOLVING MIRNA AND MIRNA INHIBITOR MOLECULES.
HZ429991 - JP 2014217387-A/144: METHODS AND COMPOSITIONS INVOLVING MIRNA AND MIRNA INHIBITOR MOLECULES.
HZ460226 - WO 2015190542-A/232: Kit or device and method for detecting biliary tract cancer.
HZ462152 - WO 2015190591-A/307: Kit and method for detecting breast cancer.
HZ501722 - JP 2016025853-A/238: MICRORNA-BASED METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF SOLID CANCERS.
HZ769248 - JP 2014223080-A/144: METHODS AND COMPOSITIONS INVOLVING MIRNA AND MIRNA INHIBITOR MOLECULES.
HZ795502 - JP 2016064989-A/4: Pharmaceutical composition for treating cancer and Method of determining sensitivity for treatment with PD-1 inhibitor.
JA058642 - Sequence 144 from Patent EP2298893.
JA059445 - Sequence 144 from Patent EP2298894.
JA073768 - Sequence 144 from Patent EP2281887.
JA104905 - Sequence 144 from Patent EP2302051.
JA106245 - Sequence 144 from Patent EP2302052.
JA107048 - Sequence 144 from Patent EP2302053.
JA107851 - Sequence 144 from Patent EP2302054.
JA108654 - Sequence 144 from Patent EP2302055.
JA109457 - Sequence 144 from Patent EP2302056.
JA191973 - Sequence 144 from Patent EP2290066.
JA192872 - Sequence 144 from Patent EP2290067.
JA193771 - Sequence 144 from Patent EP2290068.
JA194670 - Sequence 144 from Patent EP2290069.
JA195569 - Sequence 144 from Patent EP2290070.
JA196468 - Sequence 144 from Patent EP2290071.
JA197367 - Sequence 144 from Patent EP2290072.
JA198266 - Sequence 144 from Patent EP2290073.
JA199165 - Sequence 144 from Patent EP2290074.
JA200064 - Sequence 144 from Patent EP2290075.
JA200963 - Sequence 144 from Patent EP2290076.
JA218085 - Sequence 144 from Patent EP2281888.
JA226236 - Sequence 144 from Patent EP2292755.
JA229091 - Sequence 144 from Patent EP2292756.
JA257362 - Sequence 144 from Patent EP2284265.
JA278642 - Sequence 144 from Patent EP2281886.
JA284528 - Sequence 144 from Patent EP2281889.
JA292581 - Sequence 144 from Patent EP2287303.
JA317767 - Sequence 144 from Patent EP2314688.
JA374826 - Sequence 144 from Patent EP2322616.
JA526088 - Sequence 238 from Patent EP2369011.
JA526595 - Sequence 238 from Patent EP2369012.
JA527102 - Sequence 238 from Patent EP2369013.
JA536031 - Sequence 238 from Patent EP2371971.
JA788036 - Sequence 238 from Patent EP2479285.
JA788534 - Sequence 238 from Patent EP2479286.
JA810868 - Sequence 238 from Patent EP2468890.
JA811366 - Sequence 238 from Patent EP2468891.
JA811864 - Sequence 238 from Patent EP2468893.
JA812362 - Sequence 238 from Patent EP2468894.
JA812860 - Sequence 238 from Patent EP2468895.
JA813358 - Sequence 238 from Patent EP2468896.
JA813856 - Sequence 238 from Patent EP2468897.
JA814354 - Sequence 238 from Patent EP2468898.
JA814852 - Sequence 238 from Patent EP2468899.
JA817095 - Sequence 238 from Patent EP2468892.
JA825907 - Sequence 238 from Patent EP2471956.
JA826405 - Sequence 238 from Patent EP2471958.
JB024692 - Sequence 238 from Patent EP2505668.
JB025190 - Sequence 238 from Patent EP2505669.
JB037960 - Sequence 76 from Patent WO2012107841.
JB079577 - Sequence 238 from Patent EP2487252.
JB080075 - Sequence 238 from Patent EP2487253.
JB080573 - Sequence 238 from Patent EP2487254.
JB081071 - Sequence 238 from Patent EP2487255.
JB081569 - Sequence 238 from Patent EP2487256.
JB082067 - Sequence 238 from Patent EP2487257.
JB082565 - Sequence 238 from Patent EP2487258.
JB083063 - Sequence 238 from Patent EP2487259.
JB083561 - Sequence 238 from Patent EP2487260.
JB084059 - Sequence 238 from Patent EP2487261.
JB084557 - Sequence 238 from Patent EP2487262.
JB085055 - Sequence 238 from Patent EP2487263.
JB087733 - Sequence 238 from Patent EP2502630.
JB147937 - Sequence 238 from Patent EP2484782.
JB148435 - Sequence 238 from Patent EP2484783.
JB153160 - Sequence 238 from Patent EP2514433.
JB153658 - Sequence 238 from Patent EP2514434.
JB622247 - Sequence 238 from Patent EP2586454.
JB622745 - Sequence 238 from Patent EP2586455.
JC001808 - Sequence 238 from Patent EP2591794.
JC221669 - Sequence 144 from Patent EP2471923.
JC268235 - Sequence 144 from Patent EP2471924.
JC340543 - Sequence 144 from Patent EP2471922.
JC469789 - Sequence 144 from Patent EP2471921.
JC990578 - Sequence 144 from Patent EP2808390.
JD007813 - Sequence 8 from Patent EP2689033.
LF714681 - JP 2016165292-A/144: METHODS AND COMPOSITIONS INVOLVING MIRNA AND MIRNA INHIBITOR MOLECULES.
LF856615 - JP 2015142597-A/144: METHODS AND COMPOSITIONS INVOLVING MicroRNA.
LG051665 - KR 1020150036642-A/931: CHIRAL CONTROL.
LQ101371 - Sequence 76 from Patent WO2015101653.
LQ276086 - Sequence 76 from Patent WO2016071729.
LY495853 - KR 1020170015509-A/232: DETECTION KIT OR DEVICE AND DETECTION METHOD FOR BILIARY TRACT CANCER.
LY499155 - KR 1020170018412-A/307: BREAST CANCER DETECTION KIT OR DEVICE, AND METHOD FOR DETECTING BREAST CANCER.
MA259179 - JP 2017502699-A/76: LUNG CANCER DETERMINATIONS USING MIRNA RATIOS.
MS869018 - Sequence 232 from Patent EP3156500.
MS880470 - Sequence 307 from Patent EP3156498.
MS881448 - Sequence 9 from Patent EP3171879.
HZ460376 - WO 2015190542-A/382: Kit or device and method for detecting biliary tract cancer.
HZ462426 - WO 2015190591-A/581: Kit and method for detecting breast cancer.
LY496003 - KR 1020170015509-A/382: DETECTION KIT OR DEVICE AND DETECTION METHOD FOR BILIARY TRACT CANCER.
LY499429 - KR 1020170018412-A/581: BREAST CANCER DETECTION KIT OR DEVICE, AND METHOD FOR DETECTING BREAST CANCER.
MS869168 - Sequence 382 from Patent EP3156500.
MS880744 - Sequence 581 from Patent EP3156498.
HZ795500 - JP 2016064989-A/2: Pharmaceutical composition for treating cancer and Method of determining sensitivity for treatment with PD-1 inhibitor.
AJ560754 - Homo sapiens microRNA miR-197.
CQ873696 - Sequence 115 from Patent WO2004076622.
CS166359 - Sequence 70 from Patent WO2005078096.
CS265336 - Sequence 78 from Patent EP1627925.
CS444391 - Sequence 78 from Patent WO2006108473.
CS548329 - Sequence 1359 from Patent EP1777301.
DD413533 - Regulation of Mammalian Cells.
DI443633 - KR 1020140074997-A/254: MICRORNAS IN NEURODEGENERATIVE DISORDERS.
DI487337 - KR 1020100049079-A/3: Differential Expression of MicroRNAs in Nonfailing Versus Failing Human Hearts.
DL231908 - Method for the determination of cellular transcriptional regulation.
DM174460 - A nucleics Acid regulating cell growth.
FU261466 - MICRORNA EXPRESSION ABNORMALITIES IN PANCREATIC ENDOCRINE AND ACINAR TUMORS.
FU763968 - MICRORNA FINGERPRINTS DURING HUMAN MEGAKARYOCYTOPOIESIS.
FV524329 - Nucleic acid controling mast cell degranulation.
FW301827 - A METHOD OF PRODUCING RECOMBINANT BIOLOGICAL PRODUCTS.
FW312071 - DETECTING NUCLEIC ACIDS.
FW364096 - Oligonucleotides for modulating target RNA activity.
FW371735 - Human-derived nuclear acids for inhibiting HIV protein expression.
FW371752 - Human-derived nuclear acids for inhibiting HIV protein expression.
HH981274 - Sequence 34 from Patent EP1723162.
HI528966 - Sequence 46 from Patent EP2142659.
HI550223 - Sequence 3 from Patent EP2179060.
HI560981 - Sequence 196 from Patent EP2190992.
HI965331 - Sequence 616 from Patent WO2010139812.
HI966488 - Sequence 808 from Patent WO2010139811.
HI967354 - Sequence 808 from Patent WO2010139810.
HV304867 - JP 2009531018-A/434: MICRORNA-BASED METHODS AND COMPOSITIONS FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF LUNG CANCER.
HV305365 - JP 2009531019-A/434: MICRORNA-BASED METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF SOLID CANCERS.
HV534425 - WO 2011111715-A/941: Nucleic acid for controlling cell cycle.
HV543913 - JP 2011217617-A/24: Method for testing fibrosis of chronic liver diseases using miRNAs.
HV585152 - JP 2010533503-A/3: DIFFERENTIAL EXPRESSION OF MICRORNAS IN NONFAILING VERSUS FAILING HUMAN HEARTS.
HV594082 - JP 2010538653-A/196: MIRNA EXPRESSION IN HUMAN PERIPHERAL BLOOD MICROVESICLES AND USES THEREOF.
HV595001 - JP 2010539959-A/382: Micromirs.
HV749989 - WO 2012063894-A/11: A composition comprising an antisense oligonucleotide of miRNA.
HV954079 - JP 2012518421-A/991: METHODS OF DETECTING LUNG CANCER.
HW054997 - JP 2012526132-A/17: LIPOPHILIC POLYNUCLEOTIDE CONJUGATES.
HW061412 - JP 2012529295-A/17: Chemical Modification Motifs for miRNA Inhibitors and Mimetics.
HW065003 - JP 2012528797-A/15: Therapeutic and diagnostic molecules.
HW119574 - JP 2013046612-A/434: MICRORNA-BASED METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF SOLID CANCERS.
HW122397 - JP 2013504331-A/56: MICRO-RNA, AUTOANTIBODY AND PROTEIN MARKERS FOR DIAGNOSIS OF NEURONAL INJURY.
HW289837 - JP 2013520158-A/80: REENGINEERING MRNA PRIMARY STRUCTURE FOR ENHANCED PROTEIN PRODUCTION.
HW504669 - JP 2014503192-A/17: Base Modified Oligonucleotides.
HW523251 - JP 2014507123-A/36: BLOOD-BORNE MIRNAS AS SURROGATE MARKERS OF DRUG EFFICACY FOR CARDIAC CONDITIONS.
HW581817 - JP 2014511677-A/9: DISTINGUISHING BENIGN AND MALIGNANT INDETERMINATE THYROID LESIONS.
HW581827 - JP 2014511677-A/19: DISTINGUISHING BENIGN AND MALIGNANT INDETERMINATE THYROID LESIONS.
HW589903 - JP 2013121348-A/434: MICRORNA FINGERPRINTS DURING HUMAN MEGAKARYOCYTOPOIESIS.
HW669787 - JP 2013537538-A/518: THERAPEUTIC USES OF MICROVESICLES AND RELATED MICRORNAS.
HW807959 - JP 2014534810-A/254: MICRORNAS IN NEURODEGENERATIVE DISORDERS.
HW913250 - JP 2015504307-A/10: METHODS OF DIAGNOSING AND TREATING IDIOPATHIC PULMONARY FIBROSIS.
HZ073997 - JP 2013535982-A/88: Single-Stranded RNAi Agents Containing an Internal, Non-Nucleic Acid Spacer.
HZ082765 - JP 2015513906-A/122: Stem Cell Microparticles.
HZ157558 - JP 2015130862-A/382: Micromirs.
HZ184853 - JP 2015143222-A/15: Therapeutic and diagnostic molecules.
HZ186409 - JP 2015146814-A/158: Oligonucleotides for modulating target RNA activity.
HZ392574 - JP 2015180203-A/80: REENGINEERING MRNA PRIMARY STRUCTURE FOR ENHANCED PROTEIN PRODUCTION.
HZ413707 - JP 2014060993-A/434: MICRORNA-BASED METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF SOLID CANCERS.
HZ436546 - JP 2015529450-A/122: Stem Cell Microparticles.
HZ479911 - JP 2015535430-A/417: TERMINALLY MODIFIED RNA.
HZ501918 - JP 2016025853-A/434: MICRORNA-BASED METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF SOLID CANCERS.
HZ789842 - JP 2016504050-A/1587: SIGNAL-SENSOR POLYNUCLEOTIDES FOR THE ALTERATION OF CELLULAR PHENOTYPES.
HZ795499 - JP 2016064989-A/1: Pharmaceutical composition for treating cancer and Method of determining sensitivity for treatment with PD-1 inhibitor.
JA401369 - Sequence 616 from Patent WO2011080318.
JA402347 - Sequence 616 from Patent WO2011080315.
JA403354 - Sequence 616 from Patent WO2011080316.
JA405985 - Sequence 616 from Patent EP2336353.
JA427040 - Sequence 373 from Patent WO2011072177.
JA429511 - Sequence 616 from Patent WO2011095623.
JA526284 - Sequence 434 from Patent EP2369011.
JA526791 - Sequence 434 from Patent EP2369012.
JA527298 - Sequence 434 from Patent EP2369013.
JA536227 - Sequence 434 from Patent EP2371971.
JA642083 - Sequence 203 from Patent EP2386637.
JA663368 - Sequence 203 from Patent EP2385122.
JA663585 - Sequence 203 from Patent EP2385123.
JA682664 - Sequence 132 from Patent WO2011149354.
JA715209 - Sequence 991 from Patent EP2401406.
JA757880 - Sequence 13 from Patent WO2012010584.
JA788232 - Sequence 434 from Patent EP2479285.
JA788730 - Sequence 434 from Patent EP2479286.
JA791697 - Sequence 99 from Patent WO2012089772.
JA792320 - Sequence 35 from Patent WO2012089630.
JA811064 - Sequence 434 from Patent EP2468890.
JA811562 - Sequence 434 from Patent EP2468891.
JA812060 - Sequence 434 from Patent EP2468893.
JA812558 - Sequence 434 from Patent EP2468894.
JA813056 - Sequence 434 from Patent EP2468895.
JA813554 - Sequence 434 from Patent EP2468896.
JA814052 - Sequence 434 from Patent EP2468897.
JA814550 - Sequence 434 from Patent EP2468898.
JA815048 - Sequence 434 from Patent EP2468899.
JA817291 - Sequence 434 from Patent EP2468892.
JA826103 - Sequence 434 from Patent EP2471956.
JA826601 - Sequence 434 from Patent EP2471958.
JA829639 - Sequence 22 from Patent WO2013010906.
JA885406 - Sequence 36 from Patent WO2012083004.
JB022193 - Sequence 35 from Patent WO2013026685.
JB022941 - Sequence 195 from Patent WO2013026684.
JB024415 - Sequence 35 from Patent EP2505663.
JB024888 - Sequence 434 from Patent EP2505668.
JB025386 - Sequence 434 from Patent EP2505669.
JB029522 - Sequence 46 from Patent EP2481805.
JB029582 - Sequence 46 from Patent EP2481806.
JB037962 - Sequence 78 from Patent WO2012107841.
JB073411 - Sequence 22 from Patent EP2546358.
JB074959 - Sequence 219 from Patent WO2012168448.
JB079773 - Sequence 434 from Patent EP2487252.
JB080271 - Sequence 434 from Patent EP2487253.
JB080769 - Sequence 434 from Patent EP2487254.
JB081267 - Sequence 434 from Patent EP2487255.
JB081765 - Sequence 434 from Patent EP2487256.
JB082263 - Sequence 434 from Patent EP2487257.
JB082761 - Sequence 434 from Patent EP2487258.
JB083259 - Sequence 434 from Patent EP2487259.
JB083757 - Sequence 434 from Patent EP2487260.
JB084255 - Sequence 434 from Patent EP2487261.
JB084753 - Sequence 434 from Patent EP2487262.
JB085251 - Sequence 434 from Patent EP2487263.
JB087929 - Sequence 434 from Patent EP2502630.
JB148133 - Sequence 434 from Patent EP2484782.
JB148631 - Sequence 434 from Patent EP2484783.
JB153356 - Sequence 434 from Patent EP2514433.
JB153854 - Sequence 434 from Patent EP2514434.
JB175014 - Sequence 46 from Patent WO2012101219.
JB249332 - Sequence 100 from Patent EP2478360.
JB256115 - Sequence 34 from Patent EP2327710.
JB292165 - Sequence 203 from Patent EP2428569.
JB302280 - Sequence 203 from Patent EP2428570.
JB320235 - Sequence 203 from Patent EP2428568.
JB336298 - Sequence 203 from Patent EP2428571.
JB358428 - Sequence 15 from Patent EP2438167.
JB361485 - Sequence 203 from Patent EP2428567.
JB616230 - Sequence 60 from Patent WO2013107459.
JB620050 - Sequence 30 from Patent WO2013063544.
JB620172 - Sequence 152 from Patent WO2013063544.
JB622443 - Sequence 434 from Patent EP2586454.
JB622941 - Sequence 434 from Patent EP2586455.
JB624162 - Sequence 46 from Patent EP2610347.
JB624376 - Sequence 196 from Patent EP2610342.
JB770381 - Sequence 8 from Patent EP2604690.
JB778631 - Sequence 10 from Patent WO2013078283.
JC002004 - Sequence 434 from Patent EP2591794.
JC008809 - Sequence 8 from Patent WO2013088338.
JC030412 - Sequence 11 from Patent EP2638912.
JC032805 - Sequence 77 from Patent WO2013160474.
JC171750 - Sequence 122 from Patent WO2013150303.
JC244521 - Sequence 141 from Patent WO2012020308.
JC244863 - Sequence 491 from Patent WO2012020308.
JC270127 - Sequence 518 from Patent WO2012020307.
JC334165 - Sequence 83 from Patent EP2487240.
JC512574 - Sequence 2827 from Patent WO2014113089.
JC572561 - Sequence 122 from Patent WO2014125276.
JC582249 - Sequence 122 from Patent WO2014125277.
JC963973 - Sequence 8 from Patent EP2816114.
JD007814 - Sequence 9 from Patent EP2689033.
JD007824 - Sequence 19 from Patent EP2689033.
JE829072 - Sequence 8 from Patent EP2829613.
JE867361 - Sequence 168 from Patent WO2015128671.
JE953945 - Sequence 122 from Patent WO2015052526.
JE955698 - Sequence 122 from Patent WO2015052527.
LF137450 - JP 2016507550-A/122: Method of Producing Microparticles.
LF161922 - JP 2016513950-A/1988: Oligomers with improved off-target profile.
LF162415 - JP 2016513095-A/122: Stem Cell Microparticles and miRNA.
LF636316 - JP 2016519076-A/90: COMBINATION CANCER TREATMENTS UTILIZING MICRORNA AND EGFR-TKI INHIBITORS.
LF642599 - JP 2016518826-A/17: BRIDGED BICYCLIC NUCLEOSIDES.
LF644451 - JP 2016144439-A/42: Method for assessing cell aging.
LF953167 - JP 2016534103-A/122: Stem Cell Microparticles and miRNA.
LG005512 - KR 1020150004822-A/122: STEM CELL MICROPARTICLES.
LG046476 - KR 1020150023687-A/21: Oligonucleotide-Based Inhibitors Comprising Locked Nucleic Acid Motif.
LG053208 - KR 1020150059168-A/122: STEM CELL MICROPARTICLES.
LG134473 - KR 1020150131312-A/90: COMBINATION CANCER TREATMENTS UTILIZING MICRORNAS AND EGFR-TKI INHIBITORS.
LG240447 - KR 1020160035087-A/122: STEM CELL MICROPARTICLES AND MIRNA.
LP637018 - Sequence 68 from Patent EP2848702.
LP727114 - Sequence 808 from Patent EP2883966.
LP769482 - Sequence 9 from Patent EP3294910.
LP819384 - Sequence 808 from Patent EP3296406.
LP939326 - Sequence 808 from Patent EP3184651.
LP951679 - Sequence 185 from Patent WO2017157650.
LQ070162 - Sequence 486 from Patent EP2964234.
LQ101373 - Sequence 78 from Patent WO2015101653.
LQ276088 - Sequence 78 from Patent WO2016071729.
LQ278673 - Sequence 212 from Patent WO2016066288.
LQ422116 - Sequence 54 from Patent EP3026121.
LQ441212 - Sequence 219 from Patent EP3029157.
LQ565040 - Sequence 65 from Patent WO2016139092.
LQ724739 - Sequence 372 from Patent WO2018096084.
LQ840911 - Sequence 21 from Patent EP3354734.
LV470532 - JP 2016534036-A/122: Stem Cell Microparticles and miRNA.
LV746096 - JP 2015521626-A/21: OLIGONUCLEOTIDE-BASED INHIBITORS COMPRISING LOCKED NUCLEIC ACID MOTIF.
LX154520 - JP 2017509333-A/168: Biomarkers for Endometriosis.
LX270584 - JP 2016056210-A/518: THERAPEUTIC USES OF MICROVESICLES AND RELATED MICRORNAS.
LX280769 - JP 2016105097-A/56: MICRO-RNA, AUTOANTIBODY AND PROTEIN MARKERS FOR DIAGNOSIS OF NEURONAL INJURY.
LY405066 - KR 1020160117535-A/371: POLY OLIGOMER COMPOUND WITH BIOCLEAVABLE CONJUGATES.
LY504706 - KR 1020170035932-A/95: MICRORNA BIOMARKER FOR THE DIAGNOSIS OF GASTRIC CANCER.
LZ233766 - JP 2017184756-A/158: Oligonucleotides for modulating target RNA activity.
LZ234387 - JP 2017181518-A/56: MICRO-RNA, AUTOANTIBODY AND PROTEIN MARKERS FOR DIAGNOSIS OF NEURONAL INJURY.
LZ242987 - JP 2017525350-A/95: MICRORNA BIOMARKER FOR THE DIAGNOSIS OF GASTRIC CANCER.
MA259087 - JP 2017500894-A/3: NUCLEIC ACID MARKERS FOR RAPID DIAGNOSIS OF KAWASAKI DISEASE AND KIT FOR DETECTION OF THE NUCLEIC ACID MARKERS.
MA259181 - JP 2017502699-A/78: LUNG CANCER DETERMINATIONS USING MIRNA RATIOS.
MA260305 - JP 2017505623-A/371: POLY OLIGOMER COMPOUND WITH BIOCLEAVABLE CONJUGATES.
MS637895 - Sequence 12 from Patent WO2017037190.
MS673392 - Sequence 195 from Patent EP3135774.
MS833491 - Sequence 196 from Patent EP3112464.
MS834470 - Sequence 616 from Patent EP3112479.
MS881447 - Sequence 8 from Patent EP3171879.
MS901562 - Sequence 35 from Patent EP3156505.
MS944839 - Sequence 95 from Patent EP3177739.
MA643663 - JP 2017113010-A/1587: SIGNAL-SENSOR POLYNUCLEOTIDES FOR THE ALTERATION OF CELLULAR PHENOTYPES.
MA730731 - JP 2017125065-A/518: THERAPEUTIC USES OF MICROVESICLES AND RELATED MICRORNAS.
MA731547 - JP 2017140048-A/417: TERMINALLY MODIFIED RNA.
MA400822 - JP 2018515097-A/9: Method for Diagnosis and Prognosis of Chronic Heart Failure.
MA405543 - WO 2018155427-A/317: A probe with reduced false positive binding, a method to desing the probe, and the use thereof.
MA806106 - WO 2018199275-A/366: Kit, device and method for detection of ovary tumor.
MA806378 - WO 2018199275-A/638: Kit, device and method for detection of ovary tumor.
MA800716 - JP 2018183181-A/1587: SIGNAL-SENSOR POLYNUCLEOTIDES FOR THE ALTERATION OF CELLULAR PHENOTYPES.
MA822534 - WO 2019004436-A/347: Kit, device, and method for detection of lung cancer.
MA822866 - WO 2019004436-A/679: Kit, device, and method for detection of lung cancer.
MP129222 - Sequence 122 from Patent EP3470073.
MP162145 - Sequence 122 from Patent WO2019069093.
MP168036 - Sequence 43 from Patent EP3469101.
MA896078 - JP 2017217007-A/21: OLIGONUCLEOTIDE-BASED INHIBITORS COMPRISING LOCKED NUCLEIC ACID MOTIF.
MB017933 - JP 2018506997-A/65: SIGNATURE OF HEALTH.
MB119582 - WO 2019117257-A/104: Method of aiding detection of breast cancer.
MB120022 - WO 2019117306-A/44: Method of aiding detection of Alzheimer's disease.
MB119144 - WO 2019107568-A/126: Programmable Gene Expression System.
MB120038 - WO 2019117306-A/60: Method of aiding detection of Alzheimer's disease.
MB420674 - JP 2019154320-A/42: Method for evaluating cell quality.
MB481463 - JP 2019528758-A/43: Methods And Compositions For Prostate Cancer Diagnosis And Treatment.
MC003356 - WO 2020032228-A/11: Kit and method for detecting prostate cancer.
MC003367 - WO 2020032228-A/22: Kit and method for detecting prostate cancer.
MP395002 - Sequence 100 from Patent EP3565903.

-  Biochemical and Signaling Pathways
  Reactome (by CSHL, EBI, and GO)

Protein P08754 (Reactome details) participates in the following event(s):

R-HSA-8850560 G-protein alpha releases G-protein heterotrimer from PDCL
R-HSA-392206 G alpha (i) inhibits adenylate cyclase
R-HSA-392212 G alpha (i) auto-inactivates by hydrolysing GTP to GDP
R-HSA-392202 Dissociation of the P2Y purinoceptor 12:Gi complex
R-HSA-749454 The Ligand:GPCR:Gi complex dissociates
R-HSA-751001 Inactive G alpha (i) reassociates with G beta:gamma
R-HSA-170674 Dissociation of the Gi alpha:G olf complex
R-HSA-167433 G-protein beta-gamma subunits rebind the alpha-GDP subunit
R-HSA-112037 Inactivation of PLC beta
R-HSA-167415 G-protein alpha subunit is inactivated
R-HSA-111870 Activation of PLC beta-1/4
R-HSA-112271 The receptor:G-protein complex dissociates
R-HSA-167429 The receptor:G-protein complex binds GTP
R-HSA-170671 G alpha-olf:GTP binds to Gi alpha1:GTP:adenylate cyclase complex
R-HSA-170686 Adenylate cyclase increases the GTPase activity of Gi alpha
R-HSA-392187 Activated P2Y purinoceptor 12 binds G-protein Gi
R-HSA-749456 Liganded Gi-activating GPCRs bind inactive heterotrimeric G-protein Gi
R-HSA-167408 The high affinity receptor complex binds to G-protein
R-HSA-167419 The receptor:G-protein complex releases GDP
R-HSA-392195 Gi activation by P2Y purinoceptor 12
R-HSA-380073 Liganded Gi-activating GPCR acts as a GEF for Gi
R-HSA-170666 Adenylate cyclase increases the GTPase activity of G alpha-olf
R-HSA-111879 PIP2 hydrolysis
R-HSA-6814122 Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding
R-HSA-170670 Adenylate cyclase inhibitory pathway
R-HSA-418594 G alpha (i) signalling events
R-HSA-392170 ADP signalling through P2Y purinoceptor 12
R-HSA-202040 G-protein activation
R-HSA-112043 PLC beta mediated events
R-HSA-390466 Chaperonin-mediated protein folding
R-HSA-112040 G-protein mediated events
R-HSA-997269 Inhibition of adenylate cyclase pathway
R-HSA-388396 GPCR downstream signalling
R-HSA-392518 Signal amplification
R-HSA-111885 Opioid Signalling
R-HSA-391251 Protein folding
R-HSA-991365 Activation of GABAB receptors
R-HSA-372790 Signaling by GPCR
R-HSA-76002 Platelet activation, signaling and aggregation
R-HSA-392499 Metabolism of proteins
R-HSA-977444 GABA B receptor activation
R-HSA-162582 Signal Transduction
R-HSA-109582 Hemostasis
R-HSA-977443 GABA receptor activation
R-HSA-112314 Neurotransmitter receptors and postsynaptic signal transmission
R-HSA-112315 Transmission across Chemical Synapses
R-HSA-112316 Neuronal System

-  Other Names for This Gene
  Alternate Gene Symbols: ENST00000369851.1, ENST00000369851.2, ENST00000369851.3, ENST00000369851.4, ENST00000369851.5, ENST00000369851.6, GNAI3_HUMAN, NM_006496, P08754, P17539, Q5TZX1, uc318hxi.1, uc318hxi.2
UCSC ID: ENST00000369851.7_5
RefSeq Accession: NM_006496.4
Protein: P08754 (aka GNAI3_HUMAN or GBAK_HUMAN)

-  Gene Model Information
  Click here for a detailed description of the fields of the table above.

-  Methods, Credits, and Use Restrictions
  Click here for details on how this gene model was made and data restrictions if any.